Blood-brain transfer of Pittsburgh compound B in humans

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Blood-brain transfer of Pittsburgh compound B in humans. / Gjedde, Albert; Aanerud, Joel; Braendgaard, Hans; Rodell, Anders B.

In: Frontiers in Aging Neuroscience, Vol. 5, 2013, p. 70.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Gjedde, A, Aanerud, J, Braendgaard, H & Rodell, AB 2013, 'Blood-brain transfer of Pittsburgh compound B in humans', Frontiers in Aging Neuroscience, vol. 5, pp. 70. https://doi.org/10.3389/fnagi.2013.00070

APA

Gjedde, A., Aanerud, J., Braendgaard, H., & Rodell, A. B. (2013). Blood-brain transfer of Pittsburgh compound B in humans. Frontiers in Aging Neuroscience, 5, 70. https://doi.org/10.3389/fnagi.2013.00070

Vancouver

Gjedde A, Aanerud J, Braendgaard H, Rodell AB. Blood-brain transfer of Pittsburgh compound B in humans. Frontiers in Aging Neuroscience. 2013;5:70. https://doi.org/10.3389/fnagi.2013.00070

Author

Gjedde, Albert ; Aanerud, Joel ; Braendgaard, Hans ; Rodell, Anders B. / Blood-brain transfer of Pittsburgh compound B in humans. In: Frontiers in Aging Neuroscience. 2013 ; Vol. 5. pp. 70.

Bibtex

@article{42f265778e81463a911aa6d2e4bc16de,
title = "Blood-brain transfer of Pittsburgh compound B in humans",
abstract = "In the labeled form, the Pittsburgh compound B (2-(4'-{N-methyl-[(11)C]}methyl-aminophenyl)-6-hydroxy-benzothiazole, [(11)C]PiB), is used as a biomarker for positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer's disease (AD). The permeability of [(11)C]PiB in the blood-brain barrier is held to be high but the permeability-surface area product and extraction fractions in patients or healthy volunteers are not known. We used PET to determine the clearance associated with the unidrectional blood-brain transfer of [(11)C]PiB and the corresponding cerebral blood flow rates in frontal lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer's disease and healthy volunteers. Regional cerebral blood flow rates differed significantly between the two groups. Thus, regional and whole-brain permeability-surface area products were identical, in agreement with the observation that numerically, but insignificantly, unidirectional blood-brain clearances are lower and extraction fractions higher in the patients. The evidence of unchanged permeability-surface area products in the patients implies that blood flow changes can be deduced from the unidirectional blood-brain clearances of [(11)C]PiB in the patients.",
author = "Albert Gjedde and Joel Aanerud and Hans Braendgaard and Rodell, {Anders B}",
year = "2013",
doi = "10.3389/fnagi.2013.00070",
language = "English",
volume = "5",
pages = "70",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Blood-brain transfer of Pittsburgh compound B in humans

AU - Gjedde, Albert

AU - Aanerud, Joel

AU - Braendgaard, Hans

AU - Rodell, Anders B

PY - 2013

Y1 - 2013

N2 - In the labeled form, the Pittsburgh compound B (2-(4'-{N-methyl-[(11)C]}methyl-aminophenyl)-6-hydroxy-benzothiazole, [(11)C]PiB), is used as a biomarker for positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer's disease (AD). The permeability of [(11)C]PiB in the blood-brain barrier is held to be high but the permeability-surface area product and extraction fractions in patients or healthy volunteers are not known. We used PET to determine the clearance associated with the unidrectional blood-brain transfer of [(11)C]PiB and the corresponding cerebral blood flow rates in frontal lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer's disease and healthy volunteers. Regional cerebral blood flow rates differed significantly between the two groups. Thus, regional and whole-brain permeability-surface area products were identical, in agreement with the observation that numerically, but insignificantly, unidirectional blood-brain clearances are lower and extraction fractions higher in the patients. The evidence of unchanged permeability-surface area products in the patients implies that blood flow changes can be deduced from the unidirectional blood-brain clearances of [(11)C]PiB in the patients.

AB - In the labeled form, the Pittsburgh compound B (2-(4'-{N-methyl-[(11)C]}methyl-aminophenyl)-6-hydroxy-benzothiazole, [(11)C]PiB), is used as a biomarker for positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer's disease (AD). The permeability of [(11)C]PiB in the blood-brain barrier is held to be high but the permeability-surface area product and extraction fractions in patients or healthy volunteers are not known. We used PET to determine the clearance associated with the unidrectional blood-brain transfer of [(11)C]PiB and the corresponding cerebral blood flow rates in frontal lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer's disease and healthy volunteers. Regional cerebral blood flow rates differed significantly between the two groups. Thus, regional and whole-brain permeability-surface area products were identical, in agreement with the observation that numerically, but insignificantly, unidirectional blood-brain clearances are lower and extraction fractions higher in the patients. The evidence of unchanged permeability-surface area products in the patients implies that blood flow changes can be deduced from the unidirectional blood-brain clearances of [(11)C]PiB in the patients.

U2 - 10.3389/fnagi.2013.00070

DO - 10.3389/fnagi.2013.00070

M3 - Journal article

C2 - 24223554

VL - 5

SP - 70

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

ER -

ID: 118393152